LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager

LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager

Colorectal cancer (CRC) is one of the most common cancers worldwide and demands more effective treatments. We sought to identify tumor selective CRC antigens and their therapeutic potential for cytotoxic T-cell targeting by transcriptomic and immunohistochemical analysis. LY6G6D was identified as a...

Full description

Bibliographic Details
Main Authors: Leticia Corrales, Susanne Hipp, Katharina Martin, Nicolas Sabarth, Iñigo Tirapu, Klaus Fuchs, Barbara Thaler, Christian Walterskirchen, Kathrin Bauer, Markus Fabits, Michael Bergmann, Carina Binder, Paolo ML. Chetta, Anne B. Vogt, Paul J. Adam
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
LY6G6D
CD3
TcE (T cell engager)
CRC (colorectal cancer)
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1008764/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1008764/full

Similar Items